Market Research Logo

Multiple Sclerosis  - Market Insight, Epidemiology and Market Forecast - 2027

DelveInsight’s ‘Multiple Sclerosis - Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Multiple Sclerosis in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Multiple Sclerosis from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan

Study Period: 2016-2027

Multiple Sclerosis- Disease Understanding and Treatment Algorithm
The DelveInsight Multiple Sclerosis market report gives the thorough understanding of the Multiple Sclerosis by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Multiple Sclerosis in the US, Europe, and Japan.

Multiple Sclerosis Epidemiology
The Multiple Sclerosis (MS) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report is segmented by Gender [male/female], age group [≤19 years, 20-29 years, 30-39 years, 40-49 years, 50-59 years, 60-69 years, 70-79 years, and ≥80 years], sub-types [Relapsing Remitting MS, Primary Progressive MS and Progressive relapsing MS] and Expanded disability status scale (EDSS) [0.0-1.5, 2.0-3.5, 4.0-5.5, 6.0-7.5 and 8.0-9.5].

According to DelveInsight, the prevalent population of Multiple Sclerosis was estimated to be 1.98 Million [7MM] in 2016 and, is expected to increase at a CAGR of XX% during the study period i.e., 2016-2027. United States accounts for the highest MS Cases, followed by EU5 (Germany, France, Italy, Spain & UK) and Japan. In United States, the peak prevalence has been observed in patients aged 45–49 years in both female and male participants.

Multiple Sclerosis Drug Chapters
This segment of the Multiple Sclerosis report encloses the detailed analysis of marketed drugs and late stage (Phase-III) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

The drugs marketed for the treatment of mainly include disease-modifying therapies (DMT) – Copaxone , Tecfidera , Gilenya , Tysabri , Avonex, Aubagio , Lemtrada , Ocrevus , Rebif , Betaseron , Extavia , Plegridy , Fampyra , and Zinbryta . Detailed chapters for all of these drugs, along with the upcoming therapies i.e., [Siponimod (Novartis), Ponesimod (Johnson and Johnson), Ozanimod (Celgene), Ofatumumab (Novartis), Ublituximab (TG Therapeutics), ALKS 8700 (Alkermes Plc), and Mavenclad (Merck KgaA)] have been covered in the report.

Multiple Sclerosis Market Outlook
The Multiple Sclerosis market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the global market of Multiple Sclerosis was estimated to be USD 21.25 billion in 2016, and is expected to increase at a CAGR of XX% from 2016-2027.

Multiple Sclerosis Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The market size of Multiple Sclerosis includes the drug-uptake for individual therapies, which is further segmented on the basis of market size and market share by Line of therapy and Route of Administration.

Multiple Sclerosis Report Insights
• Patient Population
• Therapeutic Approaches
• Pipeline Analysis
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Multiple Sclerosis Report Key Strengths
• 10 Year Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition

Multiple Sclerosis Report Assessment
• Current Treatment Practices
• Unmet Needs
• Detailed Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Benefits
• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Multiple Sclerosis market
• Organize sales and marketing efforts by identifying the best opportunities for Multiple Sclerosis market
• To understand the future market competition in the Multiple Sclerosis market.


1. Report Introduction
2. Multiple Sclerosis Market Overview at a Glance
2.1. Market Share Distribution of Multiple Sclerosis in 2017
2.2. Market Share Distribution of Multiple Sclerosis in 2027
3. Disease Background and Overview: Multiple Sclerosis (MS)
3.1. Introduction
3.2. Risk Factors
3.3. Causes
3.4. Symptoms
3.5. Pathogenesis
3.6. Diagnosis
3.7. Expanded Disability Status Scale (EDSS)
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. Prevalent Population of Multiple Sclerosis in 7MM
4.4. Prevalent Population of Multiple Sclerosis in 7MM – By Region
4.5. Prevalent Population of Multiple Sclerosis in 7MM – Distribution (2017)
4.6. Prevalent Population of Multiple Sclerosis in 7MM – Distribution (2027)
5. Epidemiology of Multiple Sclerosis
6. United States
6.1. Assumptions and Rationale
6.2. Prevalent Population of Multiple Sclerosis in United States
6.3. Sex-Specific Prevalence of Multiple Sclerosis in United States
6.4. Sub-type Specific Prevalence of Multiple Sclerosis in United States
6.5. Age-Specific Prevalence of Multiple Sclerosis in United States
6.6. Prevalence of Multiple Sclerosis based on EDSS Score in United States
7. Germany
7.1. Assumptions and Rationale
7.2. Prevalent Population of Multiple Sclerosis in Germany
7.3. Sex-Specific Prevalence of Multiple Sclerosis in Germany
7.4. Sub-type Specific Prevalence of Multiple Sclerosis in Germany
7.5. Age-Specific Prevalence of Multiple Sclerosis in Germany
7.6. Prevalence of Multiple Sclerosis based on EDSS Score in Germany
8. France
8.1. Assumptions and Rationale
8.2. Prevalent Population of Multiple Sclerosis in France
8.3. Sex-Specific Prevalence of Multiple Sclerosis in France
8.4. Sub-type Specific Prevalence of Multiple Sclerosis in France
8.5. Age-Specific Prevalence of Multiple Sclerosis in France
8.6. Prevalence of Multiple Sclerosis based on EDSS Score in France
9. Italy
9.1. Assumptions and Rationale
9.2. Prevalent Population of Multiple Sclerosis in Italy
9.3. Sex-Specific Prevalence of Multiple Sclerosis in Italy
9.4. Sub-type Specific Prevalence of Multiple Sclerosis in Italy
9.5. Age-Specific Prevalence of Multiple Sclerosis in Italy
9.6. Prevalence of Multiple Sclerosis based on EDSS Score in Italy
10. Spain
10.1. Assumptions and Rationale
10.2. Prevalent Population of Multiple Sclerosis in Spain
10.3. Sex-Specific Prevalence of Multiple Sclerosis in Spain
10.4. Sub-type Specific Prevalence of Multiple Sclerosis in Spain
10.5. Age-Specific Prevalence of Multiple Sclerosis in France
10.6. Prevalence of Multiple Sclerosis based on EDSS Score in Spain
11. United Kingdom
11.1. Assumptions and Rationale
11.2. Prevalent Population of Multiple Sclerosis in United Kingdom
11.3. Sex-Specific Prevalence of Multiple Sclerosis in United Kingdom
11.4. Sub-type Specific Prevalence of Multiple Sclerosis in United Kingdom
11.5. Age-Specific Prevalence of Multiple Sclerosis in United Kingdom
11.6. Prevalence of Multiple Sclerosis based on EDSS Score in United Kingdom
12. Japan
12.1. Assumptions and Rationale
12.2. Prevalent Population of Multiple Sclerosis in Japan
12.3. Sex-Specific Prevalence of Multiple Sclerosis in Japan
12.4. Sub-type Specific Prevalence of Multiple Sclerosis in Japan
12.5. Age-Specific Prevalence of Multiple Sclerosis in Japan
12.6. Prevalence of Multiple Sclerosis based on EDSS Score in Japan
13. Treatment Algorithm
13.1. Association of British Neurologists: Revised Guidelines for prescribing disease-modifying treatments in Multiple Sclerosis (2015)
13.2. Overcoming barriers in Progressive Multiple Sclerosis treatment
14. Unmet Needs
15. Marketed Drugs
16. Betaferon: Bayer Healthcare
16.1. Drug Description
16.2. Mechanism of Action
16.3. Regulatory Milestones
16.4. Advantages & Disadvantages
16.5. Safety and Efficacy
16.6. Product Profile
17. Rebif: Merck KGA
17.1. Drug Description
17.2. Mechanism of Action
17.3. Regulatory Milestones
17.4. Advantages & Disadvantages
17.5. Safety and Efficacy
17.6. Product Profile
18. Copaxone: Teva Pharmaceutical
18.1. Drug Description
18.2. Mechanism of action
18.3. Regulatory Milestones
18.4. Advantages & Disadvantages
18.5. Safety and Efficacy of Copaxone
18.6. Product Profile
19. Avonex: Biogen Idec. Limited
19.1. Drug Description
19.2. Mechanism of action
19.3. Regulatory Milestones
19.4. Advantages & Disadvantages
19.5. Safety and efficacy
19.6. Product Profile
20. Tysabri: Biogen Idec. Limited
20.1. Drug Description
20.2. Mechanism of action
20.3. Regulatory Milestones
20.4. Advantages & Disadvantages
20.5. Safety and efficacy of Tysabri
20.6. Product Profile
21. Fampyra/Ampyra: Acorda Therapeutics/ Biogen Idec Ltd.
21.1. Drug Description
21.2. Mechanism of action
21.3. Regulatory Milestones
21.4. Advantages & Disadvantages
21.5. Safety and efficacy of Ampyra
21.6. Product Profile
22. Gilenya: Novartis
22.1. Drug Description
22.2. Mechanism of action
22.3. Regulatory Milestones
22.4. Advantages & Disadvantages
22.5. Safety and efficacy of Gilenya
22.6. Product Profile
23. Aubagio: Genzyme
23.1. Drug Description
23.2. Mechanism of action
23.3. Regulatory Milestones
23.4. Advantages & Disadvantages
23.5. Safety and efficacy
23.6. Product Profile
24. Tecfidera: Biogen Idec Ltd.
24.1. Drug Description
24.2. Mechanism of action
24.3. Regulatory Milestones
24.4. Advantages & Disadvantages
24.5. Safety and efficacy
24.6. Product Profile
25. Plegridy: Biogen Idec Ltd.
25.1. Drug Description
25.2. Mechanism of action
25.3. Regulatory Milestones
25.4. Advantages & Disadvantages
25.5. Safety and efficacy
25.6. Product Profile
26. Lemtrada: Genzyme
26.1. Drug Description
26.2. Mechanism of action
26.3. Regulatory Milestones
26.4. Advantages & Disadvantages
26.5. Safety and efficacy
26.6. Product Profile
27. Zinbryta: Biogen Idec
27.1. Drug Description
27.2. Mechanism of action
27.3. Regulatory Milestones
27.4. Advantages & Disadvantages
27.5. Safety and efficacy
27.6. Product Profile
28. Ocrevus: Genentech
28.1. Drug Description
28.2. Mechanism of action
28.3. Regulatory Milestones
28.4. Advantages & Disadvantages
28.5. Safety and efficacy
28.6. Product Profile
29. Mavenclad: Merck
29.1. Drug Description
29.2. Mechanism of action
29.3. Regulatory Milestones
29.4. Safety and efficacy
29.5. Advantages & Disadvantages
29.6. Product Profile
30. Emerging Therapies
30.1. Key Cross Competition
30.2. Phase III Drugs
30.3. ALKS 8700: Biogen
30.3.1. Other development activities
30.3.2. Clinical Development
30.3.3. Clinical Trials Information
30.3.4. Safety and Efficacy
30.3.5. Advantages and Disadvantages
30.3.6. Product Profile
30.4. Ublituximab: TG Therapeutics
30.4.1. Other development activities
30.4.2. Clinical Development
30.4.3. Clinical Trials Information
30.4.4. Safety and Efficacy
30.4.5. Advantages and Disadvantages
30.4.6. Product Profile
30.5. Ozanimod: Celgene Corporation
30.5.1. Other development activities
30.5.2. Clinical Development
30.5.3. Clinical Trials Information
30.5.4. Safety and Efficacy
30.5.5. Advantages and Disadvantages
30.5.6. Product Profile
30.6. OMB157: Novartis
30.6.1. Other development activities
30.6.2. Clinical Development
30.6.3. Clinical Trials Information
30.6.4. Safety and Efficacy
30.6.5. Advantages and Disadvantages
30.6.6. Product Profile
30.7. MD1003: MedDay Pharma
30.7.1. Other development activities
30.7.2. Clinical Development
30.7.3. Clinical Trials Information
30.7.4. Safety and Efficacy
30.7.5. Advantages and Disadvantages
30.7.6. Product Profile
30.8. Masitinib: AB Science
30.8.1. Other regulatory milestone
30.8.2. Clinical Development
30.8.3. Clinical Trials Information
30.8.4. Safety and Efficacy
30.8.5. Advantages and Disadvantages
30.8.6. Product Profile
30.9. Siponimod: Novartis
30.9.1. Other development activities
30.9.2. Clinical Development
30.9.3. Clinical Trials Description
30.9.4. Safety and Efficacy
30.9.5. Advantages and Disadvantages
30.9.6. Product Profile
30.10. Ponesimod: Johnson & Johnson
30.10.1. Other regulatory milestones
30.10.2. Clinical Development
30.10.3. Clinical Trials Description
30.10.4. Safety and Efficacy
30.10.5. Advantages and Disadvantages
30.10.6. Product Profile
31. Global Market Size of Multiple Sclerosis (MS)
31.1. Global Market Size ($ MM) by Therapies
31.2. Global Market Share (%) by Line of Therapies
31.3. Global Market Size ($ MM) by Line of Therapies
31.4. Global Market Share of Therapies (%) by Route of Administration (RoA)
31.5. Global Market Size ($ MM) by Route of Administration (RoA)
32. United States
32.1. Market Size of Multiple Sclerosis in United States
32.2. Market Size by Therapies
33. EU5
33.1. Market Size of Multiple Sclerosis in EU5
33.2. Market Size of MS by Therapies in EU5
34. EU-5 broken down by countries
34.1. Market Size of MS in Germany
34.2. Market Size of MS in France
34.3. Market Size of MS in Italy
34.4. Market Size of MS in Spain
34.5. Market Size of MS in United Kingdom
35. Japan
35.1. Market Size of Multiple Sclerosis in Japan
35.2. Market Size by Therapies
36. Trends observed in MS therapies Cost in United States
37. Generic Competition in MS Market
38. Market Drivers
39. Market Barriers
40. Appendix
41. Report Methodology
41.1. Sources Used
42. Consulting Services
43. Disclaimer
44. About DelveInsight
List Of Tables
Table 1: Expanded Disability Status Scale (EDSS)
Table 2: Total Prevalent Population of Multiple Sclerosis in 7 MM (2016-2027)
Table 3: Prevalent Population of Multiple Sclerosis in 7MM- By Region (2016-2027)
Table 4: Prevalent Population of Multiple Sclerosis in United States (2016-2027)
Table 5: Sex-Specific Prevalent Population of Multiple Sclerosis in United States (2016-2027)
Table 6: Sub-type Specific Prevalent Population of Multiple Sclerosis in United States (2016-2027)
Table 7: Age Specific Prevalent Population of Multiple Sclerosis in United States (2016-2027)
Table 8: Prevalent Population of Multiple Sclerosis based on EDSS Score in United States (2016-2027)
Table 9: Prevalent Population of Multiple Sclerosis in Germany (2016-2027)
Table 10: Sex-Specific Prevalent Population of Multiple Sclerosis in Germany (2016-2027)
Table 11: Sub-type Specific Prevalent Population of Multiple Sclerosis in Germany (2016-2027)
Table 12: Age Specific Prevalent Population of Multiple Sclerosis in Germany (2016-2027)
Table 13: Prevalent Population of Multiple Sclerosis based on EDSS Score in Germany (2016-2027)
Table 14: Prevalent Population of Multiple Sclerosis in France (2016-2027)
Table 15: Sex-Specific Prevalent Population of Multiple Sclerosis in France (2016-2027)
Table 16: Sub-type Specific Prevalent Population of Multiple Sclerosis in France (2016-2027)
Table 17: Age Specific Prevalent Population of Multiple Sclerosis in France (2016-2027)
Table 18: Prevalent Population of Multiple Sclerosis based on EDSS Score in France (2016-2027)
Table 19: Prevalent Population of Multiple Sclerosis in Italy (2016-2027)
Table 20: Sex-Specific Prevalent Population of Multiple Sclerosis in Italy (2016-2027)
Table 21: Sub-type Specific Prevalent Population of Multiple Sclerosis in Italy (2016-2027)
Table 22: Age Specific Prevalent Population of Multiple Sclerosis in Italy (2016-2027)
Table 23: Prevalent Population of Multiple Sclerosis based on EDSS Score in Italy (2016-2027)
Table 24: Prevalent Population of Multiple Sclerosis in Spain (2016-2027)
Table 25: Sex-Specific Prevalent Population of Multiple Sclerosis in Spain (2016-2027)
Table 26: Sub-type Specific Prevalent Population of Multiple Sclerosis in Spain (2016-2027)
Table 27: Age Specific Prevalent Population of Multiple Sclerosis in Spain (2016-2027)
Table 28: Prevalent Population of Multiple Sclerosis based on EDSS Score in Spain (2016-2027)
Table 29: Prevalent Population of Multiple Sclerosis in United Kingdom (2016-2027)
Table 30: Prevalent Population of Multiple Sclerosis in United Kingdom (2016-2027)
Table 31: Sub-type Specific Prevalent Population of Multiple Sclerosis in United Kingdom (2016-2027)
Table 32: Age Specific Prevalent Population of Multiple Sclerosis in United Kingdom (2016-2027)
Table 33: Prevalent Population of Multiple Sclerosis based on EDSS Score in United Kingdom (2016-2027)
Table 34: Prevalent Population of Multiple Sclerosis in Japan (2016-2027)
Table 35: Sex-Specific Prevalent Population of Multiple Sclerosis in Japan (2016-2027)
Table 36: Sub-type Specific Prevalent Population of Multiple Sclerosis in Japan(2016-2027)
Table 37: Age Specific Prevalent Population of Multiple Sclerosis in Japan (2016-2027)
Table 38: Prevalent Population of Multiple Sclerosis based on EDSS Score in Japan (2016-2027)
Table 39:Medications for the treatment of MS
Table 40: Comparison of emerging drugs under development
Table 41: ALKS 8700 Clinical Trial Description, 2018
Table 42: Ublituximab, Clinical Trial Description, 2018
Table 43: RPC1063, Clinical Trial Description, 2018
Table 44: Ofatumumab, Clinical Trial Description, 2018
Table 45: MD1003, Clinical Trial Description, 2018
Table 46: Masitinib, Clinical Trial Description, 2018
Table 47: BAF312, Clinical Trial Description, 2018
Table 48: Ponesimod, Clinical Trial Description, 2018
Table 49: Global Market Size of Multiple Sclerosis (MS) in USD, Million (2016-2027)
Table 50: Global Market Size of Multiple Sclerosis (MS) by Therapies in USD, Million (2016-2027)
Table 51: Global Market Share of Multiple Sclerosis (MS) by Line of Therapies in USD, Million (2017 & 2027)
Table 52: Global Market Size of Multiple Sclerosis (MS) by Line of Therapies in USD, Million (2017 & 2027)
Table 53: Global Market share of Multiple Sclerosis (MS) therapies by RoA in USD, Million (2017 & 2027)
Table 54: Global Market size of Multiple Sclerosis (MS) therapies by RoA in USD, Million (2017 & 2027)
Table 55: US Market Size of Multiple Sclerosis (MS) in USD, Million (2016-2027)
Table 56: US Market Size of Multiple Sclerosis (MS) by Therapies in USD, Million (2016-2027)
Table 57: EU5 Market Size of Multiple Sclerosis (MS) in USD, Million (2016-2027)
Table 58: EU5 Market Size of Multiple Sclerosis (MS) by Therapies in USD, Million (2016-2027)
Table 59: Germany Market Size of Multiple Sclerosis in USD, Million (2016-2027)
Table 60: France Market Size of Multiple Sclerosis in USD, Million (2016-2027)
Table 61: Italy Market Size of Multiple Sclerosis in USD, Million (2016-2027)
Table 62: Spain Market Size of Multiple Sclerosis in USD, Million (2016-2027)
Table 63: UK Market Size of Multiple Sclerosis in USD, Million (2016-2027)
Table 64: Japan Market Size of Multiple Sclerosis (MS) in USD, Million (2016-2027)
Table 65:Japan Market Size of Multiple Sclerosis (MS) by Therapies in USD, Million (2016-2027)
List Of Figures
Figure 1: Types of MS 14
Figure 2: Risk factors associated with MS 16
Figure 3: The immunological complexity of the immune/cytokine network in multiple sclerosis 21
Figure 4: Total Prevalent Population of Multiple Sclerosis in 7 MM (2016-2027) 33
Figure 5: Prevalent Population of Multiple Sclerosis in 7MM- By Region(2016-2027) 34
Figure 6: Prevalent Population of Multiple Sclerosis in United States (2016-2027) 39
Figure 7: Sex- Specific Prevalent Population of Multiple Sclerosis in United States (2016-2027) 40
Figure 8: Sub-type Specific Prevalent Population of Multiple Sclerosis in United States (2016-2027) 41
Figure 9: Age Specific Prevalent Population of Multiple Sclerosis in United States (2016-2027) 42
Figure 10: Prevalent Population of Multiple Sclerosis based on EDSS Score in US (2016-2027) 43
Figure 11: Prevalent Population of Multiple Sclerosis in Germany (2016-2027) 46
Figure 12: Sex- Specific Prevalent Population of Multiple Sclerosis in Germany (2016-2027) 47
Figure 13: Sub-type Specific Prevalent Population of Multiple Sclerosis in Germany (2016-2027) 48
Figure 14: Age Specific Prevalent Population of Multiple Sclerosis in Germany (2016-2027) 49
Figure 15: Prevalent Population of Multiple Sclerosis based on EDSS Score in Germany (2016-2027) 50
Figure 16: Prevalent Population of Multiple Sclerosis in France (2016-2027) 53
Figure 17: Sex- Specific Prevalent Population of Multiple Sclerosis in France (2016-2027) 54
Figure 18: Sub-type Specific Prevalent Population of Multiple Sclerosis in France (2016-2027) 55
Figure 19: Age Specific Prevalent Population of Multiple Sclerosis in France (2016-2027) 56
Figure 20: Prevalent Population of Multiple Sclerosis based on EDSS Score in France (2016-2027) 57
Figure 21: Prevalent Population of Multiple Sclerosis in Italy (2016-2027) 60
Figure 22: Sex- Specific Prevalent Population of Multiple Sclerosis in Italy (2016-2027) 61
Figure 23: Sub-type Specific Prevalent Population of Multiple Sclerosis in Italy (2016-2027) 62
Figure 24: Age Specific Prevalent Population of Multiple Sclerosis in Italy (2016-2027) 63
Figure 25: Prevalent Population of Multiple Sclerosis based on EDSS Score in Italy (2016-2027) 64
Figure 26: Prevalent Population of Multiple Sclerosis in Spain (2016-2027) 67
Figure 27: Sex- Specific Prevalent Population of Multiple Sclerosis in Spain (2016-2027) 68
Figure 28: Sub-type Specific Prevalent Population of Multiple Sclerosis in Spain (2016-2027) 69
Figure 29: Age Specific Prevalent Population of Multiple Sclerosis in Spain (2016-2027) 70
Figure 30: Prevalent Population of Multiple Sclerosis based on EDSS Score in Spain (2016-2027) 71
Figure 31: Prevalent Population of Multiple Sclerosis in United Kingdom (2016-2027) 74
Figure 32: Sex- Specific Prevalent Population of Multiple Sclerosis in United Kingdom (2016-2027) 75
Figure 33: Sub-type Specific Prevalent Population of Multiple Sclerosis in United Kingdom (2016-2027) 76
Figure 34: Age Specific Prevalent Population of Multiple Sclerosis in United Kingdom (2016-2027) 77
Figure 35: Prevalent Population of Multiple Sclerosis based on EDSS Score in UK (2016-2027) 78
Figure 36: Prevalent Population of Multiple Sclerosis in Japan (2016-2027) 81
Figure 37: Sex- Specific Prevalent Population of Multiple Sclerosis in Japan (2016-2027) 82
Figure 38: Sub-type Specific Prevalent Population of Multiple Sclerosis in Japan (2016-2027) 83
Figure 39: Age Specific Prevalent Population of Multiple Sclerosis in Japan (2016-2027) 84
Figure 40: Prevalent Population of Multiple Sclerosis based on EDSS Score in Japan (2016-2027) 85
Figure 41: Treatment algorithm for Multiple Sclerosis 87
Figure 42: Diagnosis and Therapy selection 92
Figure 43: Global Market Size of Multiple Sclerosis (MS) in USD, Million (2016-2027) 180
Figure 44: Global Market Size of Multiple Sclerosis (MS) by Therapies in USD, Million (2016-2027) 181
Figure 45: Global Market Share of Multiple Sclerosis (MS) by Line of Therapies in USD, Million (2017 & 2027) 182
Figure 46: Global Market Size of Multiple Sclerosis (MS) by Line of Therapies in USD, Million (2017 & 2027) 183
Figure 47: Global Market share of Multiple Sclerosis (MS) therapies by RoA (2017 & 2027) 184
Figure 48: Global Market size of Multiple Sclerosis (MS) therapies by RoA in USD, Million (2017 & 2027) 185
Figure 49: US Market Size of Multiple Sclerosis (MS) in USD, Million (2016-2027) 191
Figure 50: US Market Size of Multiple Sclerosis (MS) by Therapies in USD, Million (2016-2027) 192
Figure 51: EU5 Market Size of Multiple Sclerosis (MS) in USD, Million (2016-2027) 194
Figure 52: EU5 Market Size of Multiple Sclerosis (MS) by Therapies in USD, Million (2016-2027) 195
Figure 53: Germany Market Size of Multiple Sclerosis in USD, Million (2016-2027) 196
Figure 54: France Market Size of Multiple Sclerosis in USD, Million (2016-2027) 197
Figure 55: Italy Market Size of Multiple Sclerosis in USD, Million (2016-2027) 198
Figure 56: Spain Market Size of Multiple Sclerosis in USD, Million (2016-2027) 199
Figure 57: UK Market Size of Multiple Sclerosis in USD, Million (2016-2027) 200
Figure 58: Japan Market Size of Multiple Sclerosis (MS) in USD, Million (2016-2027) 202
Figure 59: Japan Market Size of Multiple Sclerosis (MS) by Therapies in USD, Million (2016-2027) 203
Figure 60: Market Drivers 208
Figure 61:Market Barriers 210

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report